arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Royalty Pharma plc

RPRX

$67.54 ▼ -0.02 (-0.03%) at close

8 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Excellent

Bullish

auto_awesome

Analytical Summary

Royalty Pharma plc shows strong fundamentals with top-quartile Profit Margin (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $29.0B

Dividend Yield —

Revenue Growth 5.1% ↗

Op. Margin 65.6% ↗

ROIC 17.4% ↗

FCF / Share $5.79 ↘

Trailing P/E 37.7x

Price / Book —

FCF Yield 8.6%

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$2.38B

↑ +5.1% —

Net Income Profit after all expenses

$770.95M

↓ -10.2% —

Operating Margin Operating profit as % of sales

65.6%

↑ +14.8% 99th

FCF / Share Free cash flow per share

$5.79

↓ -6.2% —

Long-Term Debt Long-term obligations

$8.95B

↑ +17.6% —

trending_up

Bullish Indicators

Operating Margin (%)Operating Margin (%) is in the top quartile
Profit Margin (%)Profit Margin (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Profitability ↑

Financial Health ↓

Cash Quality →

Dividend History

Dividend / share · sourced from SEC filings

$0.80 Latest / share

+5.3% YoY

+38.7% 4-yr CAGR

FY 2018

FY 2019

$0.30

FY 2020

$0.68

FY 2021

$0.76

FY 2022

$0.80

FY 2023

FY 2024

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 7 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	5.1% Fair ↑ Fair Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-37%)	-3.9% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-148%)	5.2% Fair ↓ Fair Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-34%)	-2.3% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-129%)	7.9% Fair ↓ Fair Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: At sector avg	17.0% Good Good Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+112%)	1.1% Caution Caution Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-87%)	—
EPS Growth YoY (%)	-6.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-24.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	2440.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-93.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	12.9% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-10.2% Weak ↓ Weak Declining Year-over-year change in net income	-24.3% Weak ↓ Weak Declining Year-over-year change in net income	2549.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-93.1% Weak ↓ Weak Declining Year-over-year change in net income	-36.4% Weak ↓ Weak Declining Year-over-year change in net income	-58.5% Weak Weak Year-over-year change in net income	70.5% Excellent Excellent Year-over-year change in net income	—
FCF Growth YoY (%)	-6.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	-7.4% Weak ↓ Weak Declining Year-over-year change in free cash flow	36.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	0.6% Caution Caution Year-over-year change in free cash flow	-10.2% Weak Weak Year-over-year change in free cash flow	—	—	—
Revenue CAGR 3Y (%)	2.1% Caution ↓ Caution Declining Compound annual revenue growth over 3 years	-0.4% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	3.5% Caution ↓ Caution Declining Compound annual revenue growth over 3 years	7.2% Fair Fair Compound annual revenue growth over 3 years	8.5% Fair Fair Compound annual revenue growth over 3 years	—	—	—
Revenue CAGR 5Y (%)	2.3% Caution ↓ Caution Declining Compound annual revenue growth over 5 years	4.5% Fair Fair Compound annual revenue growth over 5 years	5.6% Fair Fair Compound annual revenue growth over 5 years	—	—	—	—	—
EPS CAGR 3Y (%)	161.6% Excellent ↑ Excellent Improving Compound annual EPS growth over 3 years	8.8% Fair Fair Compound annual EPS growth over 3 years	24.4% Excellent Excellent Compound annual EPS growth over 3 years	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Operating Margin (%) (%)	65.6% Excellent ↑ Excellent Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+337%)	57.1% Excellent ↑ Excellent Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+281%)	63.4% Excellent ↑ Excellent Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+322%)	13.7% Fair ↓ Fair Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-8%)	62.5% Excellent ↓ Excellent Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+317%)	75.2% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+401%)	—	76.0% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+407%)
Effective Tax Rate (%) (%)	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%
Profit Margin (%) (%)	32.4% Excellent ↑ Excellent Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+170%)	37.9% Excellent ↑ Excellent Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+216%)	48.2% Excellent ↑ Excellent Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+302%)	1.9% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-84%)	27.1% Excellent ↓ Excellent Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+126%)	45.9% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+283%)	—	76.8% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+540%)
FCF Margin (%) (%)	104.7% Excellent ↓ Excellent Declining Free cash flow as a percentage of revenue Optimal: > 10%	122.3% Excellent ↑ Excellent Improving Free cash flow as a percentage of revenue Optimal: > 10%	126.9% Excellent ↑ Excellent Improving Free cash flow as a percentage of revenue Optimal: > 10%	95.8% Excellent → Excellent Stable Free cash flow as a percentage of revenue Optimal: > 10%	88.1% Excellent → Excellent Stable Free cash flow as a percentage of revenue Optimal: > 10%	95.9% Excellent ↑ Excellent Improving Free cash flow as a percentage of revenue Optimal: > 10%	91.9% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	90.2% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%
FCF / Net Income (x)	3.23x Excellent ↓ Excellent Declining Free cash flow relative to reported net income Optimal: > 1x	3.22x Excellent ↓ Excellent Declining Free cash flow relative to reported net income Optimal: > 1x	2.63x Excellent ↓ Excellent Declining Free cash flow relative to reported net income Optimal: > 1x	50.06x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	3.26x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	2.09x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.17x Fair Fair Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	17.4% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	17.0% Excellent → Excellent Stable Return earned on debt + equity capital invested Optimal: > 10%	24.3% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	4.3% Caution ↓ Caution Declining Return earned on debt + equity capital invested Optimal: > 10%	20.2% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	27.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	44.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	7.9% Fair ↑ Fair Improving Operating profit relative to total assets Optimal: > 10%	7.1% Fair ↑ Fair Improving Operating profit relative to total assets Optimal: > 10%	9.1% Fair ↑ Fair Improving Operating profit relative to total assets Optimal: > 10%	1.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	8.2% Fair ↓ Fair Declining Operating profit relative to total assets Optimal: > 10%	10.0% Fair Fair Operating profit relative to total assets Optimal: > 10%	21.1% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	—

⚖️ Is the balance sheet risky? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Interest Coverage (x)	5.64x Good → Good Stable Operating income divided by interest expense Optimal: > 5x	8.10x Good ↑ Good Improving Operating income divided by interest expense Optimal: > 5x	7.97x Good ↑ Good Improving Operating income divided by interest expense Optimal: > 5x	1.63x Caution ↓ Caution Declining Operating income divided by interest expense Optimal: > 5x	8.61x Good → Good Stable Operating income divided by interest expense Optimal: > 5x	10.16x Excellent ↑ Excellent Improving Operating income divided by interest expense Optimal: > 5x	9.77x Good Good Operating income divided by interest expense Optimal: > 5x	4.87x Fair Fair Operating income divided by interest expense Optimal: > 5x
Net Debt (USD)	$8.33B	$6.68B	$5.66B	$5.41B	$5.56B	$4.81B	$5.71B	—
Debt / EBITDA (x)	5.73x Weak ↓ Weak Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	5.89x Weak ↓ Weak Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	4.11x Weak ↓ Weak Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	23.18x Weak ↑ Weak Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	4.96x Weak ↑ Weak Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	3.65x Caution Caution Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	2.27x Fair Fair Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$5.53	$5.05	$5.26	$5.11	$5.52	$5.65	—	—
Basic EPS, GAAP (USD)	$1.79	$1.92	$2.54	$0.10	$1.49	$1.32	—	—
Free Cash Flow per Share (USD)	$5.79	$6.18	$6.68	$4.90	$4.86	$5.42	—	—
Dividend per Share (USD)	—	—	$0.80	$0.76	$0.68	$0.30	—	—
Basic Weighted Avg Shares (shares)	429.80M	448.19M	447.60M	437.96M	414.79M	375.44M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$891.88M	$548.52M	$1.11B	$1.39B	$2.71B	$2.39B	$498.65M	—
LT Debt (USD)	$8.95B	$7.61B	$6.14B	$7.12B	$7.10B	$5.82B	$5.96B	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$2.38B	$2.26B	$2.35B	$2.24B	$2.29B	$2.12B	$1.81B	$1.79B
Depreciation Expense (USD)	$3.85M	$0.00	—	—	—	—	—	—
Net Income, GAAP (USD)	$770.95M	$858.98M	$1.13B	$42.83M	$619.73M	$975.04M	$2.35B	$1.38B
Operating Cash Flow (USD)	$2.49B	$2.77B	$2.99B	$2.14B	$2.02B	$2.03B	$1.67B	$1.62B

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 8 years · 29 quarters

Royalty Pharma plc

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare RPRX with peers